“We are quite optimistic, actually, that the vaccine is – the data speaks for itself and they’ll be supportive,” Hoge said in a preview clip from a longer interview, set to air on “Dateline” Thursday night.
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet on Dec. 17 to review Moderna’s application for emergency use authorization.
The FDA also has a meeting scheduled Dec. 10 to discuss Pfizer’s application for emergency use authorization for it's Covid-19 candidate.
Once authorized, Hoge said that Moderna would be ready to ship its vaccine quickly.
Like others, he said, Moderna has partnered with Gen. Gus Perna and Operation Warp Speed: “I’ve been told they want trucks rolling within hours, if not a day.”
“So, what we’ve done is we’ve been helping to position the vaccine in the warehouses where they can access it immediately if it’s approved and start distribution,” Hoge said.
When asked by Holt if there was a plan B if the vaccine isn’t approved, Hoge said, “There hasn’t been much of a plan B since about February, you know. We’re all in on this. We hope this vaccine works.”
He added that they are confident in the data, and if FDA comes back with any questions, they will do everything they can do answer them.